Rasmussen J M, Brandslund I, Svehag S E
Acta Pathol Microbiol Immunol Scand C. 1984 Dec;92(6):335-40. doi: 10.1111/j.1699-0463.1984.tb00097.x.
The complement consuming activity and monocyte Fc-receptor (FcR) binding of some commercial IgG-preparations for intravenous (i.v.) and intramuscular (i.m.) use was investigated. A pepsin-treated IgG-preparation for i.v. use exhibited no detectable complement consuming activity and impaired FcR binding, whereas an unmodified IgG preparation had no detectable complement consuming activity, but retained full FcR binding. A preparation prepared by PEG-precipitation and ion-exchange chromatography exhibited low complement consuming activity as well as good FcR binding. Three preparations for i.m. use showed moderate to strong complement consuming activity, whereas only one of these preparations retained full FcR binding.
对一些用于静脉注射(i.v.)和肌肉注射(i.m.)的市售IgG制剂的补体消耗活性和单核细胞Fc受体(FcR)结合情况进行了研究。一种经胃蛋白酶处理的用于静脉注射的IgG制剂未表现出可检测到的补体消耗活性,且FcR结合受损,而未修饰的IgG制剂没有可检测到的补体消耗活性,但保留了完整的FcR结合能力。通过聚乙二醇沉淀和离子交换色谱法制备的一种制剂表现出低补体消耗活性以及良好的FcR结合能力。三种用于肌肉注射的制剂表现出中度至强烈的补体消耗活性,而这些制剂中只有一种保留了完整的FcR结合能力。